Tulane Cancer Center | Strategic Alliance Partners

March 01, 2019

An increasing amount of evidence shows that a proportion of patients with cancer found to have low-volume metastases at diagnosis see meaningful benefit from aggressive local therapy. Equally important, there have been no meaningful reductions in reported quality of life among patients receiving intensive local therapy, and a small percentage of patients appear to be cured with this strategy.

August 28, 2017

Oliver Sartor, MD, medical oncologist at Tulane University School of Medicine, discusses conclusions drawn from an analysis of African-American patients receiving sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer and the potential for combinations with this agent.

July 03, 2017

Research from Tulane University provides a strong case that, across demographic and clinical populations, informed patients are less wary of palliative care and more inclined to take advantage of the favorable effects that palliative care services can offer for patient-centered outcomes.

January 13, 2017

Amid a rising incidence of thyroid cancer, endocrine surgeons have increasingly explored minimally invasive approaches for operating on patients with the disease.

June 21, 2016

Oliver Sartor, MD, medical director of Tulane Cancer Center, discusses the mechanism of action of radium-223 dichloride (Xofigo) as well as its safety profile for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

March 10, 2016

Much work needs to be done to increase Lynch syndrome screening rates and better understand the factors that are associated with low testing rates.

January 27, 2016

Retreatment with radium-223 dichloride (Xofigo) after initial therapy and progression was determined to be safe in patients with bone-metastatic castration-resistant prostate cancer.

October 27, 2015

Oliver Sartor, MD, expands on the impact of the STAMPEDE and CHAARTED trials and discusses how the results may change the treatment paradigm for prostate cancer going forward.

October 26, 2015

Determining the optimal sequencing of novel agents with standard chemotherapy has become a key issue in the management of castration-resistant prostate cancer.

September 16, 2015

Oliver Sartor, MD, medical oncologist, Tulane University School of Medicine, discusses key points for community oncologists regarding radium-223 for the treatment of prostate cancer.

August 27, 2015

The alpha particle–emitting radiopharmaceutical radium-223 (Xofigo) is set to expand beyond prostate cancer, given the agent's potent efficacy and mild toxicity profile for patients with osteoblastic metastases.

August 17, 2015

Palliative care should address the unique symptom profile of gynecologic cancer and be tailored to individual socioeconomic environments.

June 30, 2015

A randomized study is underway to determine if the combination of sipuleucel-T (Provenge) and radium-223 (Xofigo) may improve outcomes in patients with metastatic castration-resistant prostate cancer.

May 27, 2015

Prescott Deininger, PhD, Professor and Regents Distinguished Chair, director, Tulane Cancer Center, Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, discusses how genetic instability plays a role in mutations that may lead to specific tumor types.

May 25, 2015

Emad Kandil, MD, Chief of Endocrine Surgery at the Tulane University School of Medicine, discusses advances in surgical procedures.

April 24, 2015

Oliver Sartor, MD, medical oncologist, Tulane University School of Medicine, discusses sequencing therapies and potential targets in prostate cancer.

April 17, 2015

Roy Weiner, MD, Associate Dean for Clinical Research and Training Associate Director of Clinical Research for Tulane Cancer Center discusses the importance of racial and ethnic diversity in cancer research.

April 09, 2015

Three-dimensional printers are on the cusp of revolutionizing the way every doctor practices medicine.

April 16, 2014

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses the distinction between symptomatic and asymptomatic patients with bone metastases from prostate cancer.

April 16, 2014

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses the distinction between symptomatic and asymptomatic patients with bone metastases from prostate cancer.